OMERS ADMINISTRATION Corp Invests $505,000 in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

OMERS ADMINISTRATION Corp purchased a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 37,900 shares of the company's stock, valued at approximately $505,000. OMERS ADMINISTRATION Corp owned approximately 0.15% of Eton Pharmaceuticals as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Nantahala Capital Management LLC boosted its holdings in Eton Pharmaceuticals by 12.0% in the fourth quarter. Nantahala Capital Management LLC now owns 1,118,483 shares of the company's stock worth $14,898,000 after purchasing an additional 119,750 shares during the last quarter. Mink Brook Asset Management LLC purchased a new stake in Eton Pharmaceuticals in the fourth quarter worth approximately $6,071,000. Cannell Capital LLC purchased a new stake in Eton Pharmaceuticals in the fourth quarter worth approximately $5,079,000. Aristides Capital LLC boosted its holdings in Eton Pharmaceuticals by 20.8% in the fourth quarter. Aristides Capital LLC now owns 241,587 shares of the company's stock worth $3,218,000 after purchasing an additional 41,587 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Eton Pharmaceuticals by 230.5% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,878 shares of the company's stock worth $2,862,000 after purchasing an additional 149,864 shares during the last quarter. Institutional investors own 27.86% of the company's stock.

Analyst Upgrades and Downgrades

ETON has been the subject of several research reports. HC Wainwright reaffirmed a "buy" rating and set a $33.00 price target on shares of Eton Pharmaceuticals in a research report on Wednesday, March 19th. B. Riley reiterated a "buy" rating and set a $26.00 price target (up previously from $24.00) on shares of Eton Pharmaceuticals in a research note on Friday, May 16th. Finally, Craig Hallum lifted their price target on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th.

Eton Pharmaceuticals Trading Down 2.2%

Shares of ETON traded down $0.44 during trading hours on Friday, reaching $19.81. 271,640 shares of the stock traded hands, compared to its average volume of 196,873. Eton Pharmaceuticals, Inc. has a 52-week low of $3.18 and a 52-week high of $21.48. The company's 50-day moving average price is $15.31 and its two-hundred day moving average price is $14.32. The company has a market cap of $531.26 million, a P/E ratio of -90.05 and a beta of 1.22.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.09 by ($0.02). The firm had revenue of $17.28 million for the quarter, compared to analysts' expectations of $14.33 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. On average, research analysts forecast that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current year.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.